Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

Core Insights - Hyperion DeFi, Inc. has appointed Hyunsu Jung as Chief Executive Officer to lead the company towards its strategic priorities for 2026 [2][3] - The leadership team is further strengthened with the appointment of David Knox as Chief Financial Officer and Robert Rubenstein as General Counsel [5][6] Leadership Appointments - Hyunsu Jung, previously Chief Investment Officer, is now CEO, focusing on on-chain business development and operational discipline [3][4] - David Knox, appointed CFO in September 2025, has extensive experience in capital markets and aims to enhance the company's financial infrastructure [5] - Robert Rubenstein will join as General Counsel on January 12, 2026, bringing nearly three decades of legal experience [6] Strategic Focus - The company aims to build a leading Hyperliquid-native DeFi platform that supports global adoption and monetizes growth through disciplined strategies [6] - Hyperion DeFi is positioned to differentiate itself in the digital asset market by focusing on fundamentals and sustainable revenue models [6] Hyperliquid Platform - Hyperliquid is a next-generation layer one blockchain designed for high-frequency trading, featuring on-chain perpetual futures and spot order books [7] - The platform supports a general-purpose smart contract environment similar to Ethereum, enhancing its utility for decentralized financial applications [7] HYPE Token - HYPE is the native token of Hyperliquid, with over 37 million tokens autonomously purchased and sequestered by the blockchain as of January 2026 [8] - Staking HYPE offers users reduced trading fees and increased referral bonuses, contributing to the ecosystem's growth [8] Company Overview - Hyperion DeFi is the first U.S. publicly listed company focused on building a strategic treasury of HYPE, providing investors access to a rapidly growing blockchain ecosystem [10] - The company is also developing the Optejet User Filled Device for ophthalmic applications, aimed at improving treatment compliance and patient outcomes [11]